MNPR earnings analysis
What we found in MNPR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q extract does not include an income statement, balance sheet, cash-flow statement, MD&A, segment data, or quantitative guidance, so current-period financial performance cannot be assessed. Risk factors were explicitly unchanged from the March 27, 2026 Form 10-K. The principal new disclosure is the adoption of six insider Rule 10b5-1 trading plans covering specified amounts of common stock, including up to 47,309 shares under the CEO's plan.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Risk profile unchanged
- The filing reports no material changes to the risk-factor information previously disclosed in the March 27, 2026 Form 10-K.
- Multiple insider trading plans filed
- Six insiders adopted Rule 10b5-1 trading arrangements. The plans cover up to 615 shares for the CFO, 47,309 shares for the CEO, 16,800 shares for the executive chairman, 16,360 shares for a director, 1,380 shares for the chief medical director, and 9,425 shares for another director.
- Executive certifications filed
- The CEO and CFO certifications were filed as Exhibits 31.1 and 31.2, and the joint certifications under Section 906 were filed as Exhibit 32.1.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Insider sale plans may pressure stock
- The CEO's Rule 10b5-1 plan provides for sales of up to 47,309 common shares through May 31, 2027, while the CFO's plan covers up to 615 shares through May 31, 2027. Planned insider sales could add trading pressure and signal potential dilution concerns.
- Broad insider selling activity
- Additional Rule 10b5-1 plans cover up to 16,800 shares for the executive chairman, 16,360 shares for a director, 9,425 shares for another director, and 1,380 shares for the chief medical director, with termination dates ranging from December 14, 2026 to July 31, 2027.
- No updated risk-factor disclosure
- The filing states there have been no material changes in the risk factors from the Annual Report on Form 10-K filed March 27, 2026; therefore, the 10-Q does not provide updated disclosure on the company's principal operating, financing, or regulatory risks.
What they said about what is next.
The provided 10-Q text contains no quantitative revenue or EPS outlook; no guidance was provided in the filing.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 14, 2026
- Monopar Therapeutics' Q1 2026 report shows continued operational losses, with a net loss of $3.9 million, translating to an EPS loss of $0.61, worse than the previous year. Despite not generating any revenue, the…
- 10-K · March 27, 2026
- Monopar remains a clinical-stage biopharmaceutical company with two principal programs: ALXN1840 for Wilson disease (licensed from Alexion) and a uPAR-targeted radiopharmaceutical program (MNPR-101). The 10-K highlights…
- 10-Q · August 12, 2025
- Monopar reported Q2 2025 net loss of $2,453,526 (EPS $(0.35)), beating the EPS consensus of $(0.48) but continuing to report zero revenue. Operating expenses increased materially (Q2 operating expenses $3,234,295 vs…
- 10-Q · May 13, 2025
- Monopar reported no revenue for the quarter and a net loss of $2,624,972 (loss per share $0.38) for the three months ended March 31, 2025, compared with a net loss of $1,641,226 (loss per share $0.51) in the prior-year…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MNPR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever